Antipodes Partners LTD Nuvalent, Inc. Transaction History
Antipodes Partners LTD
- $4.06 Billion
- Q3 2025
A detailed history of Antipodes Partners LTD transactions in Nuvalent, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 391 shares of NUVL stock, worth $37,731. This represents 0.0% of its overall portfolio holdings.
Number of Shares
391
Previous 479
18.37%
Holding current value
$37,731
Previous $36,000
8.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
211Shares Held
61.3MCall Options Held
35.1KPut Options Held
62.2K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.74 Billion28.96% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$509 Million14.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$444 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$292 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA2.3MShares$222 Million0.04% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.15B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...